Henry Schein confirms strategic investment in BioHorizons

Henry Schein has announced plans to make a strategic investment in dental implant manufacturer BioHorizons, purchasing a 60 percent share in the company.

The transaction with BioHorizons involves a two-step process, with a recapitalisation phase seeing Henry Schein lending around $145 million (88.69 million pounds) to BioHorizons, followed by the equity investment itself.

BioHorizons is a US-based manufacturer of advanced dental implants sold internationally and generates revenues of around $115 million. The investment will help Henry Schein establish a more prominent position in the growing global implant market.

Stanley Bergman, chairman of the board and chief executive officer of Henry Schein, said: "Henry Schein's strategy includes advancing our position in dental specialty markets, an integral part of which is to support those practitioners who perform oral surgery involving implants."

Earlier this month, the company announced its financial results for the third quarter of 2013, during which it generated a record net sales total of $2.3 billion.